An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

NCT00695305 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Atherosclerosis

Interventions

DRUG: rilapladib
DRUG: placebo
OTHER: 18F Fluorodeoxylucose (FDG)-PET

Sponsor

GlaxoSmithKline